CR20230614A - Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos - Google Patents
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicosInfo
- Publication number
- CR20230614A CR20230614A CR20230614A CR20230614A CR20230614A CR 20230614 A CR20230614 A CR 20230614A CR 20230614 A CR20230614 A CR 20230614A CR 20230614 A CR20230614 A CR 20230614A CR 20230614 A CR20230614 A CR 20230614A
- Authority
- CR
- Costa Rica
- Prior art keywords
- oxoisoindolin
- piperidine
- medical uses
- dione derivatives
- hemoglobinopathies
- Prior art date
Links
- WENKGSGGXGQHSH-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O WENKGSGGXGQHSH-UHFFFAOYSA-N 0.000 title 1
- 102100020716 Protein Wiz Human genes 0.000 abstract 2
- 101710186935 Protein Wiz Proteins 0.000 abstract 2
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 2
- 208000018337 inherited hemoglobinopathy Diseases 0.000 abstract 2
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud se refiere a compuestos de fórmula (I), composiciones farmacéuticas que los comprenden, y su uso para reducir los niveles de expresión de los motivos de dedos de zinc ampliamente interespaciados (WIZ), o para inducir la expresión de la hemoglobina fetal (HbF), y en el tratamiento de trastornos sanguíneos hereditarios (por ejemplo, hemoglobinopatías, por ejemplo, beta–hemoglobinopatías), tales como la enfermedad de células falciformes y beta–talasemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196422P | 2021-06-03 | 2021-06-03 | |
| PCT/IB2022/055131 WO2022254362A1 (en) | 2021-06-03 | 2022-06-01 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230614A true CR20230614A (es) | 2024-02-01 |
Family
ID=82115547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230614A CR20230614A (es) | 2021-06-03 | 2022-06-01 | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230019617A1 (es) |
| EP (1) | EP4347580A1 (es) |
| KR (1) | KR20240013812A (es) |
| CN (1) | CN117062811A (es) |
| AR (1) | AR126052A1 (es) |
| AU (1) | AU2022284366A1 (es) |
| BR (1) | BR112023024905A2 (es) |
| CA (1) | CA3215410A1 (es) |
| CO (1) | CO2024000013A2 (es) |
| CR (1) | CR20230614A (es) |
| DO (1) | DOP2023000261A (es) |
| EC (1) | ECSP24000004A (es) |
| IL (1) | IL308094A (es) |
| PE (1) | PE20240657A1 (es) |
| TW (1) | TW202306570A (es) |
| WO (1) | WO2022254362A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US20120302605A1 (en) | 2010-11-18 | 2012-11-29 | Deuteria Pharmaceuticals, Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| KR102173464B1 (ko) * | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| FI3820573T3 (fi) * | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa |
| JP2022510313A (ja) * | 2018-12-03 | 2022-01-26 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法 |
| CN115397821A (zh) * | 2019-10-17 | 2022-11-25 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| CR20220278A (es) * | 2019-12-18 | 2022-07-01 | Novartis Ag | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos |
-
2022
- 2022-06-01 TW TW111120484A patent/TW202306570A/zh unknown
- 2022-06-01 CR CR20230614A patent/CR20230614A/es unknown
- 2022-06-01 US US17/829,933 patent/US20230019617A1/en active Pending
- 2022-06-01 CN CN202280022964.9A patent/CN117062811A/zh active Pending
- 2022-06-01 CA CA3215410A patent/CA3215410A1/en active Pending
- 2022-06-01 BR BR112023024905A patent/BR112023024905A2/pt unknown
- 2022-06-01 PE PE2023003180A patent/PE20240657A1/es unknown
- 2022-06-01 AU AU2022284366A patent/AU2022284366A1/en active Pending
- 2022-06-01 AR ARP220101454A patent/AR126052A1/es unknown
- 2022-06-01 EP EP22731823.5A patent/EP4347580A1/en active Pending
- 2022-06-01 WO PCT/IB2022/055131 patent/WO2022254362A1/en active Application Filing
- 2022-06-01 IL IL308094A patent/IL308094A/en unknown
- 2022-06-01 KR KR1020237045016A patent/KR20240013812A/ko active Search and Examination
-
2023
- 2023-11-29 DO DO2023000261A patent/DOP2023000261A/es unknown
-
2024
- 2024-01-02 CO CONC2024/0000013A patent/CO2024000013A2/es unknown
- 2024-01-02 EC ECSENADI20244A patent/ECSP24000004A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347580A1 (en) | 2024-04-10 |
| AR126052A1 (es) | 2023-09-06 |
| AU2022284366A1 (en) | 2023-10-26 |
| US20230019617A1 (en) | 2023-01-19 |
| KR20240013812A (ko) | 2024-01-30 |
| BR112023024905A2 (pt) | 2024-02-20 |
| ECSP24000004A (es) | 2024-02-29 |
| PE20240657A1 (es) | 2024-04-04 |
| TW202306570A (zh) | 2023-02-16 |
| CO2024000013A2 (es) | 2024-01-25 |
| WO2022254362A1 (en) | 2022-12-08 |
| DOP2023000261A (es) | 2023-12-29 |
| CA3215410A1 (en) | 2022-12-08 |
| CN117062811A (zh) | 2023-11-14 |
| IL308094A (en) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007351A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos. | |
| EP2548880A3 (en) | Compositions for increasing telomerase activity | |
| BRPI0417186A (pt) | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica | |
| BG106825A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
| BRPI0409650A (pt) | métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica | |
| BR0210374A (pt) | Amidas de ácido antranìlico com cadeia lateral de heteroarilsulfonila, processos para produção das mesmas, uso das mesmas como medicamento ou agente de diagnóstico, bem como preparações farmacêuticas que contêm as mesmas | |
| TW200719882A (en) | Treatment of connective tissue diseases of the skin | |
| TW200612903A (en) | Use of trisubstituted benzopyranones | |
| JO2449B1 (en) | Thiosol derivatives - benziazothiazole dioxide, methods of preparation and use. | |
| CN105107007A (zh) | 一种阳离子医用护创敷料及其制备方法 | |
| ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| US20170072024A1 (en) | Antimicrobial composition comprising a carbohydrate, glucose oxidase and zinc oxide | |
| DK0832081T3 (da) | Bicykliske-aromatiske forbindelser | |
| CO2024000013A2 (es) | Derivados de 3–(1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos médicos | |
| RU2008138358A (ru) | Композиция с фиксированной дозой фитата и цинка | |
| DE502005008500D1 (de) | Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung | |
| MX2023010827A (es) | Derivados de pirazolopiridina y sus usos. | |
| ATE326959T1 (de) | Verwendung von docosahexaensäure als wirkstoff bei der behandlung von lipodystrophie | |
| EA201000739A1 (ru) | Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата | |
| WO2006087147A3 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | |
| SG11201806628UA (en) | New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | |
| DE502004011874D1 (de) | Flupirtine-präparat zur behandlung von neurodegeneetes mellitus | |
| TR200704897A1 (tr) | Uzatılmış salım sağlayan gliklazid formülasyonları@ | |
| JP2016011262A (ja) | 口腔粘膜疾患の予防または治療用経口製剤 | |
| ATE532512T1 (de) | Isoniazid-vermittelte heilung von wunden und geschwüren |